PulseExploreJournal ClubDebatesTrendingResearchersJournals
Instagram
HomeExploreJournal ClubTrending
Synapse
⌘+K
Synapse
January 15, 1998Journal of Clinical Investigation127 citationsOpen Access

Enhancement of murine cardiac chronotropy by the molecular transfer of the human beta2 adrenergic receptor cDNA.

JEJay M. EdelbergWAWilliam C. AirdRRRobert Rosenberg

Structured PICO

Does molecular transfer of human beta2AR cDNA increase cardiac chronotropy in murine models?

P
Population
Murine embryonic cardiac myocytes (in vitro), murine neonatal cardiac transplantation model (ex vivo), and endogenous adult B6D2F1 murine hearts (in vivo).
I
Intervention
Plasmid constructs encoding human beta2 adrenergic receptor (beta2AR) cDNA under the beta-actin promoter, delivered via lipofection (in vitro) or direct injection (ex vivo/in vivo).
C
Comparator
Plasmid constructs encoding the bacterial beta-galactosidase gene (LacZ) as a control expression vector.
O
Outcome
Cardiac chronotropy (myocyte contraction rate in vitro, and heart rate in ex vivo and in vivo models).surrogate

Local gene transfer of the human beta2 adrenergic receptor significantly enhances cardiac chronotropy in murine models, demonstrating a potential gene therapy approach to regulate cardiac pacemaking.

Abstract

Cardiac pacemaking offers a unique opportunity for direct gene transfer into the heart. An experimental system was developed to assay the effects of transferring the human beta2 adrenergic receptor (beta2AR) under in vitro, ex vivo, and finally in vivo conditions. Constructs encoding either beta2AR or LacZ were used in chronotropy studies with isolated myocytes, and transplanted as well as endogenous murine hearts. Murine embryonic cardiac myocytes were transiently transfected with plasmid constructs. The total percentage of myocytes spontaneously contracting was greater in beta2AR transfected cells, as compared with control cells (67 vs. 42+/-5%). In addition, the percentage of myocytes with chronotropic rates > 60 beats per minute (bpm) was higher in the beta2AR population, as compared with control cells (37 vs. 15+/-5%). The average contractile rate was greater in the beta2AR transfected myocytes at baseline (71+/-14 vs. 50+/-10 bpm; P < 0.001) as well as with the addition of 10(-)3 M isoproterenol (98+/-26 vs. 75+/-18 bpm; P < 0.05). Based on these results, a murine neonatal cardiac transplantation model was used to study the ex vivo effects of targeted expression of beta2AR. The constructs were transfected into the right atrium of transplanted hearts. Injection of the beta2AR construct increased the heart rate by approximately 40% (224+/-37 vs. 161+/-42 bpm; P < 0.005). Finally, the constructs were tested in vivo with injection into the right atrium of the endogenous heart. These results were similar to the ex vivo data with injection of the beta2AR constructs increasing the endogenous heart rates by approximately 40%, as compared with control injected hearts (550+/-42 vs. 390+/-37 bpm; P < 0.05). These studies demonstrate that local targeting of gene expression may be a feasible modality to regulate the cardiac pacemaking activity.

Ask AI
Helpful
Bookmark
Share
View Full Paper

Cite This Study

Edelberg et al. (1998) studied this question.

synapsesocial.com/papers/6a9069d2779e50c2dc90b7b6https://doi.org/10.1172/jci1330
Ask AI
Helpful
Bookmark
Share
View Full Paper